https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-01 / Vaccine 2018 05;36(23):3247-3253
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-01 / Vaccine 2018 05;36(23):3247-32532018-05-01 00:00:002019-02-15 08:45:20Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-26 / Front Oncol 2018;8:127
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-26 / Front Oncol 2018;8:1272018-04-26 00:00:002019-02-15 08:34:53Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-20 / Oncol Res Treat 2018;41(5):292-297
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-20 / Oncol Res Treat 2018;41(5):292-2972018-04-20 00:00:002020-12-07 09:37:23Immunotherapy of Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-11 / Sci Transl Med 2018 Apr;10(436)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-11 / Sci Transl Med 2018 Apr;10(436)2018-04-11 00:00:002019-02-15 08:52:24Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-01 / Anticancer Res. 2018 04;38(4):2217-2225
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-01 / Anticancer Res. 2018 04;38(4):2217-22252018-04-01 00:00:002019-02-15 08:52:40WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-30 / Oncotarget 2018 Mar;9(24):17014-170272018-03-30 00:00:002019-02-15 08:49:53Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-29 / Cancer Immunol Immunother 2018 Dec;67(12):1897-1910
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-29 / Cancer Immunol Immunother 2018 Dec;67(12):1897-19102018-03-29 00:00:002024-11-03 11:46:45Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-26 / J Immunol Res 2018;2018:8740976
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-26 / J Immunol Res 2018;2018:87409762018-03-26 00:00:002018-03-26 00:00:00Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-26 / Oncoimmunology 2018;7(7):e1445457
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-26 / Oncoimmunology 2018;7(7):e14454572018-03-26 00:00:002018-03-26 00:00:00Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-21 / Semin. Cell Dev. Biol. 2019 Feb;86:77-88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-21 / Semin. Cell Dev. Biol. 2019 Feb;86:77-882018-03-21 00:00:002019-03-25 10:43:23Dendritic cells as cancer therapeutics
